Cullinan Therapeutics (CGEM) Short Interest Ratio & Short Volume → This military-backed stock “owns” AI market (From Porter & Company) (Ad) Free CGEM Stock Alerts $23.50 +0.71 (+3.12%) (As of 05/31/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Cullinan Therapeutics Short Interest DataCurrent Short Interest3,740,000 sharesPrevious Short Interest2,360,000 sharesChange Vs. Previous Month+58.47%Dollar Volume Sold Short$99.93 millionShort Interest Ratio5.0 Days to CoverLast Record DateMay 15, 2024Outstanding Shares57,630,000 sharesFloat Size31,440,000 sharesShort Percent of Float11.90%Today's Trading Volume948,096 sharesAverage Trading Volume685,633 sharesToday's Volume Vs. Average138% Short Selling Cullinan Therapeutics ? Sign up to receive the latest short interest report for Cullinan Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartCGEM Short Interest Over TimeCGEM Days to Cover Over TimeCGEM Percentage of Float Shorted Over Time Ad Porter & CompanyThe only financial event in 2024 that matters Man Who Predicted 2008 Crash Warns of Black Swan Financial Event in 2024 Porter Stansberry’s new documentary is going viral.Stream the documentary for free by clicking here Cullinan Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 5/15/20243,740,000 shares $99.93 million +58.5%11.9%5 $26.72 4/30/20242,360,000 shares $63.74 million +40.5%10.2%3.3 $27.01 4/15/20241,680,000 shares $27.80 million +16.7%6.4%3.1 $16.55 3/31/20241,440,000 shares $24.54 million +53.9%5.5%3.4 $17.04 3/15/2024935,400 shares $14.90 million +34.8%3.6%2.3 $15.93 2/29/2024694,100 shares $12.82 million -11.5%2.6%1.8 $18.47 Get the Latest News and Ratings for CGEM and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Cullinan Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 2/15/2024783,900 shares $14.45 million -46.7%2.9%2.3 $18.43 1/31/20241,470,000 shares $22.26 million +34.9%5.4%5.1 $15.14 1/15/20241,090,000 shares $11.54 million +3.8%4.0%5.2 $10.59 12/31/20231,050,000 shares $10.70 million -48.5%3.9%5.4 $10.19 12/15/20232,040,000 shares $16.81 million -3.3%7.5%11.1 $8.24 11/30/20232,110,000 shares $17.28 million -2.3%7.8%12.5 $8.19 11/15/20232,160,000 shares $19.16 million +0.5%8.0%13.3 $8.87 10/31/20232,150,000 shares $20.06 million -1.8%7.9%12.9 $9.33 10/15/20232,190,000 shares $19.27 million -0.5%8.1%12.9 $8.80 9/30/20232,200,000 shares $19.91 million +0.9%8.1%12.1 $9.05 9/15/20232,180,000 shares $21.71 million -17.7%8.0%11.5 $9.96 8/31/20232,650,000 shares $27.43 million +33.2%9.8%10.2 $10.35 8/15/20231,990,000 shares $20.32 million +2.6%7.4%6.4 $10.21 7/31/20231,940,000 shares $20.54 million -18.5%8.2%6.1 $10.59 7/15/20232,380,000 shares $27.89 million +15.5%10.1%7.6 $11.72 6/30/20232,060,000 shares $22.17 million -11.6%8.7%6.8 $10.76 6/15/20232,330,000 shares $29.59 million +2.6%9.9%7.6 $12.70 5/31/20232,270,000 shares $23.34 million +0.9%9.6%8.6 $10.28 5/15/20232,250,000 shares $22.37 million +0.5%9.5%10.7 $9.94 4/30/20232,240,000 shares $21.80 million +0.5%9.5%10.7 $9.73 4/15/20232,230,000 shares $22.34 million +0.5%9.5%9.9 $10.02 3/31/20232,220,000 shares $22.71 million +1.8%9.4%10.2 $10.23 3/15/20232,180,000 shares $24.44 million +3.8%7.7%10.5 $11.21 2/28/20232,100,000 shares $23.71 million +1.5%7.0%13.3 $11.29 2/15/20232,070,000 shares $23.91 million +6.7%6.9%13.7 $11.55 1/31/20231,940,000 shares $22.58 million -9.4%6.6%13.7 $11.64 1/15/20232,140,000 shares $23.50 million -1.8%7.2%16.4 $10.98 12/30/20222,180,000 shares $23.00 million No Change7.4%17 $10.55 12/15/20222,180,000 shares $24.96 million No Change7.4%15.9 $11.45 11/30/20222,180,000 shares $27.10 million -5.6%7.4%14.8 $12.43 11/15/20222,310,000 shares $29.48 million -4.9%8.0%14.2 $12.76 10/31/20222,430,000 shares $31.93 million -0.4%8.5%15.4 $13.14 10/15/20222,440,000 shares $30.79 million -1.2%8.5%15.7 $12.62 9/30/20222,470,000 shares $31.67 million +14.4%8.6%14.2 $12.82Trump’s Gift Could Unleash $51 Billion in New Wealth (Ad)In January 2021, Donald Trump silently rolled out a special gift to the American public… One that top house republicans called “The Key To America’s Economic Future”.You just have to make this simple move before July 30, 2024. 9/15/20222,160,000 shares $28.21 million -13.6%7.5%10.9 $13.06 8/31/20222,500,000 shares $33.70 million No Change8.8%10.5 $13.48 8/15/20222,500,000 shares $35.40 million +2.9%8.8%8.5 $14.16 7/31/20222,430,000 shares $32.83 million -17.9%9.9%4.1 $13.51 7/15/20222,960,000 shares $43.57 million -1.7%12.1%4.9 $14.72 6/30/20223,010,000 shares $38.59 million -0.7%12.3%5.2 $12.82 6/15/20223,030,000 shares $36.09 million +6.3%12.4%5.2 $11.91 5/31/20222,850,000 shares $30.47 million +4.0%11.7%5.3 $10.69 5/15/20222,740,000 shares $29.10 million +3.8%11.2%5.7 $10.62 4/30/20222,640,000 shares $25.90 million +7.8%11.2%14.4 $9.81 4/15/20222,450,000 shares $27.44 million -3.5%10.4%13.2 $11.20 3/31/20222,540,000 shares $26.59 million -7.3%11.0%13.3 $10.47 3/15/20222,740,000 shares $34.91 million +1.5%12.1%13.2 $12.74 2/28/20222,700,000 shares $38.72 million +5.9%12.0%10.3 $14.34 2/15/20222,550,000 shares $37.69 million -3.4%11.3%9.6 $14.78 1/31/20222,640,000 shares $35.59 million -13.7%12.1%9.9 $13.48 1/15/20223,060,000 shares $41.89 million -1.0%13.4%11.4 $13.69 12/31/20213,090,000 shares $47.68 million +27.2%14.3%10.7 $15.43 12/15/20212,430,000 shares $38.71 million +3.4%11.2%9.4 $15.93 11/30/20212,350,000 shares $42.30 million -0.8%10.9%9.9 $18.00 11/15/20212,370,000 shares $49.68 million -7.8%8.1%9.3 $20.96 10/29/20212,570,000 shares $57.11 million +0.8%8.9%10.3 $22.22 10/15/20212,550,000 shares $63.75 million -1.9%8.8%10.6 $25.00 9/30/20212,600,000 shares $58.68 million +42.9%9.0%11.7 $22.57 9/15/20211,820,000 shares $52.78 million -24.5%6.3%7.6 $29.00 8/31/20212,410,000 shares $68.01 million -11.1%8.4%11.7 $28.22 8/13/20212,710,000 shares $75.09 million No Change9.5%12.4 $27.71 CGEM Short Interest - Frequently Asked Questions What is Cullinan Therapeutics' current short interest? Short interest is the volume of Cullinan Therapeutics shares that have been sold short but have not yet been closed out or covered. As of May 15th, investors have sold 3,740,000 shares of CGEM short. 11.90% of Cullinan Therapeutics' shares are currently sold short. Learn More on Cullinan Therapeutics' current short interest. What is a good short interest ratio for Cullinan Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. CGEM shares currently have a short interest ratio of 5.0. Learn More on Cullinan Therapeutics's short interest ratio. Which institutional investors are shorting Cullinan Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Cullinan Therapeutics: Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Cullinan Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 11.90% of Cullinan Therapeutics' floating shares are currently sold short. Is Cullinan Therapeutics' short interest increasing or decreasing? Cullinan Therapeutics saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 3,740,000 shares, an increase of 58.5% from the previous total of 2,360,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Cullinan Therapeutics' float size? Cullinan Therapeutics currently has issued a total of 57,630,000 shares. Some of Cullinan Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Cullinan Therapeutics currently has a public float of 31,440,000 shares. How does Cullinan Therapeutics' short interest compare to its competitors? 11.90% of Cullinan Therapeutics' shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to Cullinan Therapeutics: Xencor, Inc. (10.17%), MacroGenics, Inc. (15.21%), Black Diamond Therapeutics, Inc. (3.80%), Innate Pharma S.A. (0.09%), Merus (5.93%), CRISPR Therapeutics AG (18.05%), ImmunityBio, Inc. (38.03%), Krystal Biotech, Inc. (9.84%), Immunovant, Inc. (15.25%), SpringWorks Therapeutics, Inc. (14.43%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.81 billion), Charter Communications, Inc. ($3.30 billion), Occidental Petroleum Co. ($3.10 billion), General Motors ($2.84 billion), Moderna, Inc. ($2.77 billion), AppLovin Co. ($2.22 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.16 billion), Tractor Supply ($2.12 billion), and Williams-Sonoma, Inc. ($2.12 billion). View all of the most shorted stocks. What does it mean to sell short Cullinan Therapeutics stock? Short selling CGEM is an investing strategy that aims to generate trading profit from Cullinan Therapeutics as its price is falling. CGEM shares are trading up $0.71 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Cullinan Therapeutics? A short squeeze for Cullinan Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of CGEM, which in turn drives the price of the stock up even further. How often is Cullinan Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including CGEM, twice per month. The most recent reporting period available is May, 15 2024. More Short Interest Resources from MarketBeat Related Companies: XNCR Short Interest Data MGNX Short Interest Data BDTX Short Interest Data IPHA Short Interest Data MRUS Short Interest Data CRSP Short Interest Data IBRX Short Interest Data KRYS Short Interest Data IMVT Short Interest Data SWTX Short Interest Data Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:CGEM) was last updated on 6/2/2024 by MarketBeat.com Staff From Our PartnersBiden Nomination CANCELED?The Freeport SocietyWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProBiden replacement revealed?Paradigm PressShocking: One AI startup's revenue could surge 4,735%Manward PressNvidia has Apple and Microsoft within striking rangeWeiss RatingsDon’t buy a single NVIDIA share before you see this...Behind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cullinan Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.